Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,448,967
  • Shares Outstanding, K 61,457
  • Annual Sales, $ 77,430 K
  • Annual Income, $ -184,680 K
  • EBIT $ -266 M
  • EBITDA $ -250 M
  • 60-Month Beta 2.14
  • Price/Sales 44.04
  • Price/Cash Flow N/A
  • Price/Book 302.43

Options Overview Details

View History
  • Implied Volatility 48.71% ( -0.30%)
  • Historical Volatility 45.27%
  • IV Percentile 25%
  • IV Rank 21.67%
  • IV High 82.47% on 08/05/24
  • IV Low 39.36% on 11/19/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 2,522
  • Volume Avg (30-Day) 416
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 9,095
  • Open Int (30-Day) 8,096

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.74
  • Number of Estimates 9
  • High Estimate -0.41
  • Low Estimate -1.03
  • Prior Year -0.70
  • Growth Rate Est. (year over year) -5.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.39 +5.11%
on 12/18/24
63.44 -11.54%
on 11/27/24
-3.24 (-5.46%)
since 11/20/24
3-Month
46.80 +19.91%
on 10/10/24
68.58 -18.17%
on 11/11/24
+3.32 (+6.29%)
since 09/20/24
52-Week
35.17 +59.57%
on 05/29/24
68.58 -18.17%
on 11/11/24
+11.27 (+25.13%)
since 12/20/23

Most Recent Stories

More News
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

RYTM : 56.12 (+1.15%)
Rhythm Pharmaceuticals Receives Expanded MHRA Marketing Authorization for IMCIVREE® to Treat Obesity in Children as Young as 2 Years with Rare Genetic Conditions

Rhythm Pharmaceuticals announces expanded marketing authorization for IMCIVREE® to treat obesity in patients with specific genetic conditions.Quiver AI SummaryRhythm Pharmaceuticals, Inc. announced that...

RYTM : 56.12 (+1.15%)
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency...

RYTM : 56.12 (+1.15%)
Rhythm Pharmaceuticals Announces Positive Weight Reduction Results in Pediatric Patients Treated with Setmelanotide in Early-Access Program and Plans New Substudy for Congenital Hypothalamic Obesity

Four pediatric patients using setmelanotide therapy showed significant weight loss in a French early-access program, prompting further study.Quiver AI SummaryRhythm Pharmaceuticals announced promising...

RYTM : 56.12 (+1.15%)
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

RYTM : 56.12 (+1.15%)
Rhythm Pharmaceuticals Publishes Positive Phase 3 VENTURE Trial Results for Setmelanotide in Young Children with Rare Genetic Obesity Conditions

Rhythm Pharmaceuticals reports Phase 3 trial results showing setmelanotide reduces hunger and weight in young children with severe obesity.Quiver AI SummaryRhythm Pharmaceuticals announced positive results...

RYTM : 56.12 (+1.15%)
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

RYTM : 56.12 (+1.15%)
Rhythm Pharmaceuticals Announces New Employment Inducement Grants

RYTM : 56.12 (+1.15%)
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

RYTM : 56.12 (+1.15%)
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

RYTM : 56.12 (+1.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

3rd Resistance Point 60.39
2nd Resistance Point 59.28
1st Resistance Point 57.70
Last Price 56.12
1st Support Level 55.00
2nd Support Level 53.89
3rd Support Level 52.31

See More

52-Week High 68.58
Last Price 56.12
Fibonacci 61.8% 55.82
Fibonacci 50% 51.88
Fibonacci 38.2% 47.93
52-Week Low 35.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar